{
    "title": "106_s3051",
    "content": "The Act may be cited as the \"Greater Access to Affordable Pharmaceuticals Act\" or the \"GAAP Act of 2000.\" It pertains to new drug applications. The \"Greater Access to Affordable Pharmaceuticals Act\" or the \"GAAP Act of 2000\" amends Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act to limit the use of patents in preventing approval of Abbreviated New Drug Applications. The \"GAAP Act of 2000\" amends Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act to limit patent use in blocking Abbreviated New Drug Applications. Amendments include removing certain clauses and redesignating others. The \"GAAP Act of 2000\" amends Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act by revising clauses and removing clause (viii) for effective date changes. The \"GAAP Act of 2000\" amends Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for listed drugs without prior certification under section 505(j)(2)(A)(vii)(IV). SEC. 3. CITIZEN PETITION REVIEW. Amends the Federal Food, Drug, and Cosmetic Act regarding citizen petitions and application review by the Secretary. SEC. 4. BIOEQUIVALENCE TESTING METHODS. SEC. 4. BIOEQUIVALENCE TESTING METHODS. Amends the Federal Food, Drug, and Cosmetic Act to include new testing methods for generic drugs to demonstrate therapeutic equivalence. The Federal Food, Drug, and Cosmetic Act is amended to include new provisions regarding the date of final decisions in court actions related to patent certifications for generic drugs. The Federal Food, Drug, and Cosmetic Act is amended to include provisions for the one-hundred and eighty day period for generic drug applications if the previous applicant fails to market their product or amends their certification. These amendments only apply to applications filed after the enactment of the Act. Congress believes in promoting generic drugs to reduce healthcare costs by utilizing the patent extension procedure under the Hatch-Waxman Act. The amendment to Section 505 of the Federal Food, Drug, and Cosmetic Act aims to streamline the approval process for generic drugs by updating certain subsections. The amendment to Section 505A of the Federal Food, Drug, and Cosmetic Act focuses on pediatric studies of drugs, updating subsections to streamline the approval process for generic drugs. The amendment to Section 505A of the Federal Food, Drug, and Cosmetic Act streamlines the approval process for generic drugs by updating subsections related to pediatric studies. Additionally, Section 201 of the Act is amended to include a new definition related to court decisions. The term 'the court' in certain sections refers to the court that issues a final judgment without any appeal."
}